Microencapsulation of antibiotic rifampicin in poly(3-hydroxybutyrate-co-3-hydroxyvalerate)
Archives of Pharmacal Research, 2008The aim of this study was the preparation of microparticles containing rifampicin using a biodegradable polymer poly(3-hydroxybutyrate-co-3-hydroxyvalerate) for oral administration produced by a bacteria. The poly(3-hydroxybutyrate-co-3-hydroxyvalerate) microparticles with and without rifampicin were prepared by the emulsification and solvent ...
N, Durán +4 more
openaire +2 more sources
Synthesis of poly‐(3‐hydroxybutyrate‐co‐3‐hydroxyvalerate) by recombinant Escherichia coli
Biotechnology and Bioengineering, 1996Several recombinant Escherichia coli strains, including XL1-Blue, JM109, HB101, and DH5alpha harboring a stable high-copynumber plasmid pSYL105 containing the Alcaligenes eutrophus polyhydroxyalkanoate (PHA) biosynthesis genes were constructed.
Yim, KS +2 more
openaire +2 more sources
Anaerobic degradation of poly-3-hydroxybutyrate and poly-3-hydroxybutyrate-co-3-hydroxyvalerate
Biodegradation, 1997The anaerobic degradation of the polyesters poly-3-hydroxybutyrate (PHB) and poly-3-hydroxybutyrate-co-3-hydroxyvalerate (PHBV) was investigated with special regard to intermediate products, kinetics, and yields. During the degradation of PHBV acetate, propionate, n-butyrate, and n-valerate were detected.
A, Reischwitz, E, Stoppok, K, Buchholz
openaire +2 more sources
Microstructure of bacterially synthesized poly(3-hydroxybutyrate-co-3-hydroxyvalerate)
Macromolecules, 1989Ce ne sont pas des copolymeres statistiques simples mais des melanges de copolymeres statistiques de differentes fractions molaires d ...
N.Kamiya +4 more
openaire +1 more source
Cocrystallization of isothermally crystallized poly(3-hydroxybutyrate-co-3-hydroxyvalerate)
Macromolecules, 1992The crystalline lattices of random poly(3-hydroxybutyrate-co-3-hydroxyvalerate) were found to be independent of the crystallization temperature, whereas the composition in the crystalline phase changes. The rise in the crystallization temperature is accompanied by the decrease in the content of minor comonomer units in the crystalline phase.
N. Yoshie +3 more
openaire +1 more source
Nanofibrous poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/chitosan scaffolds for skin regeneration
International Journal of Biological Macromolecules, 2012The purpose of this study was to evaluate hybrid poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV)/chitosan nanofibrous mats as scaffolds for skin engineering. In vitro studies were carried out to test the potential of the scaffolds for fibroblasts adhesion, viability, and proliferation (L929 cell line).
Veleirinho, B. +5 more
openaire +3 more sources
Properties and Applications of Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Biocomposites
Journal of Polymers and the Environment, 2020Polyhydroxyalkanoates (PHAs) are biopolyesters accumulated by microorganisms as intracellular storage materials and they have attracted attention as “green plastic” alternatives to their petrochemical counterparts. Poly(3-hydroxybutyrate-co-3-hydroxyvalerate), PHBV, is one of the most studied members of the PHAs family, with numerous applications. PHBV
Mohammad I. Ibrahim +3 more
openaire +1 more source
In this study, a phaCR gene encoding PHA synthase was identified in Rhodoligotrophos defluvii which was adjacent to β-ketothiolase encoded by phaAR gene and acetoacetyl-CoA reductase encoded by phaBR gene. Amino acid comparison of PhaCR showed the highest homology of 65.98% with PhaC of R.
Changfeng, Miao +8 more
openaire +2 more sources
Complex composition distribution of poly(3-hydroxybutyrate-co-3-hydroxyvalerate)
Macromolecules, 1995Four commercially available samples of bacterial poly(3-hydroxybutyrate-co-3-hydroxyvalerate) [P(3HB-co-3HV)] containing from 6.5 to 21.8 mol % 3HV have been fractionated by chloroform/n-heptane mixed solvent. They have been separated into several fractions with wide composition ranges.
Naoko Yoshie +3 more
openaire +1 more source
In vitro antibiotic release from poly(3-hydroxybutyrate-co-3-hydroxyvalerate) rods
Journal of Microencapsulation, 2002Provision and maintenance of adequate concentrations of antibiotics at infection sites is very important in treating highly resistant infections. For diseases like implant related osteomyelitis (IRO) it is best to provide this locally via implanted drug formulations, as systemic administration of the antibiotic may not be effective due to damaged ...
I, Gurselt +3 more
openaire +2 more sources

